Migraine Drugs Market Expected to Reach $2,190 Million, Globally, by 2025
The market was valued at $1,713 million in 2017, and is expected to reach $2,190 million by 2025, growing at a CAGR of 3.1% from 2018 to 2025. North America is anticipated to be the highest revenue contributor throughout the forecast period. The market was valued at $1,713 million in 2017, and is expected to reach $2,190 million by 2025, growing at a CAGR of 3.1% from 2018 to 2025. North America is anticipated to be the highest revenue contributor throughout the forecast period.
Introductionof Migraine Drugs Market The market was valued at $1,713 million in 2017, and is expected to reach $2,190 million by 2025, growing at a CAGR of 3.1% from 2018 to 2025. North America is anticipated to be the highest revenue contributor throughout the forecast period. Migraine is characterized by a recurrent throbbing headache, which affects only one side of the head. It is accompanied by vomiting, nausea, and even disturbed vision in some cases. Increase in prevalence of migraine, rapid rise in female population, and surge in awareness among patients for migraine treatment & prevention drive the growth of the global migraine drugs market. However, side effects of migraine drugs are expected to limit the market growth. Conversely, emerging new therapies/drugs for migraine treatment and growth opportunities in the emerging nations are expected to present opportunities for the market growth during the forecast period.
Introductionof Migraine Drugs Market Scope of the Report Key Benefits Key Audiences
- Page 1: Opportunity Analysis and Industry F
- Page 5 and 6: Table of Content (TOC) Chapter: 1 I
- Page 7 and 8: Segments Migraine Drugs Market
- Page 9 and 10: Company Profiles Migraine Drugs Mar
Introductionof<br />
<strong>Migraine</strong> <strong>Drugs</strong> <strong>Market</strong><br />
Scope of the Report<br />
Key Benefits<br />
Key Audiences
Change language